Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage

  • Jieun Koh (Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine) ;
  • Min Jung Kim (Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine)
  • Received : 2018.04.12
  • Accepted : 2018.07.09
  • Published : 2019.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

Keywords

Acknowledgement

This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407).

References

  1. Gabriel NH, James LC, Carl JD, Stephen BE, Elizabeth AM, Hope SR, et al. Breast. In: Mahul BA, ed. American Joint Committee on Cancer (AJCC). AJCC cancer staging manual, 8th ed. New York, NY: Springer, 2017:589-628
  2. Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24 Suppl 2:S26-S35 https://doi.org/10.1016/j.breast.2015.07.008
  3. Rezo A, Dahlstrom J, Shadbolt B, Rodins K, Zhang Y, Davis AJ; ACT & SENSW BCTG. Tumor size and survival in multicentric and multifocal breast cancer. Breast 2011;20:259-263 https://doi.org/10.1016/j.breast.2011.01.005
  4. Morris EA, Schwartz LH, Drotman MB, Kim SJ, Tan LK, Liberman L, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000;214:67-72 https://doi.org/10.1148/radiology.214.1.r00ja1667
  5. Lee EJ, Han SH, Kang BJ, Kim SH. Imaging and pathologic characterization of the skin thickening or enhancement under the breast MRI. Investig Magn Reson Imaging 2016;20:9-26 https://doi.org/10.13104/imri.2016.20.1.9
  6. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998;82:2366-2372 https://doi.org/10.1002/(SICI)1097-0142(19980615)82:12<2366::AID-CNCR10>3.0.CO;2-N
  7. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 1985;74:291-297
  8. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109:417-426 https://doi.org/10.1007/s10549-007-9671-z
  9. Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, et al. MRI features of inflammatory breast cancer. AJR Am J Roentgenol 2011;197:W769-W776 https://doi.org/10.2214/AJR.10.6157
  10. Alvarez S, Anorbe E, Alcorta P, Lopez F, Alonso I, Cortes J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006;186:1342-1348 https://doi.org/10.2214/AJR.05.0936
  11. Patel T, Given-Wilson RM, Thomas V. The clinical importance of axillary lymphadenopathy detected on screening mammography: revisited. Clin Radiol 2005;60:64-71 https://doi.org/10.1016/j.crad.2004.05.007
  12. Mortellaro VE, Marshall J, Singer L, Hochwald SN, Chang M, Copeland EM, et al. Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging 2009;30:309-312 https://doi.org/10.1002/jmri.21802
  13. Valente SA, Levine GM, Silverstein MJ, Rayhanabad JA, Weng-Grumley JG, Ji L, et al. Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. Ann Surg Oncol 2012;19:1825-1830 https://doi.org/10.1245/s10434-011-2200-7
  14. Yoshimura G, Sakurai T, Oura S, Suzuma T, Tamaki T, Umemura T, et al. Evaluation of axillary lymph node status in breast cancer with MRI. Breast Cancer 1999;6:249-258 https://doi.org/10.1007/BF02967179
  15. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-432; discussion 432-433 https://doi.org/10.1097/SLA.0b013e3181f08f32
  16. Humphrey KL, Saksena MA, Freer PE, Smith BL, Rafferty EA. To do or not to do: axillary nodal evaluation after ACOSOG Z0011 trial. Radiographics 2014;34:1807-1816 https://doi.org/10.1148/rg.347130141
  17. Verheuvel NC, van den Hoven I, Ooms HW, Voogd AC, Roumen RM. The role of ultrasound-guided lymph node biopsy in axillary staging of invasive breast cancer in the post-ACOSOG Z0011 trial era. Ann Surg Oncol 2015;22:409-415 https://doi.org/10.1245/s10434-014-4071-1
  18. Farrell TP, Adams NC, Stenson M, Carroll PA, Griffin M, Connolly EM, et al. The Z0011 trial: is this the end of axillary ultrasound in the pre-operative assessment of breast cancer patients? Eur Radiol 2015;25:2682-2687 https://doi.org/10.1007/s00330-015-3683-6
  19. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988;81:1109-1112 https://doi.org/10.1097/00007611-198809000-00011
  20. Aebi S, Davidson T, Gruber G, Castiglione M; ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v9-v14 https://doi.org/10.1093/annonc/mdq159
  21. Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When and how do I use neoadjuvant chemotherapy for breast cancer? Curr Treat Options Oncol 2014;15:86-98 https://doi.org/10.1007/s11864-013-0266-0
  22. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 2011;29:4654-4661 https://doi.org/10.1200/JCO.2011.38.3174
  23. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med 2014;138:1048-1052 https://doi.org/10.5858/arpa.2013-0435-OA
  24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410 https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
  25. Elston EW, Ellis IO. Method for grading breast cancer. J Clin Pathol 1993;46:189-190
  26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-784 https://doi.org/10.1016/S0140-6736(11)60993-8
  27. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-1451 https://doi.org/10.1038/bjc.1996.563
  28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
  29. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-368 https://doi.org/10.1634/theoncologist.2008-0230
  30. Rosenthal SI, Depowski PL, Sheehan CE, Ross JS. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 2002;10:40-46 https://doi.org/10.1097/00129039-200203000-00007
  31. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283 https://doi.org/10.1056/NEJMoa0910383
  32. Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol 2015;1:1154-1161 https://doi.org/10.1001/jamaoncol.2015.2286
  33. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20 https://doi.org/10.1002/ijc.2910310104
  34. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al.; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26:1533-1546 https://doi.org/10.1093/annonc/mdv221
  35. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153 https://doi.org/10.1093/jnci/95.2.142
  36. Eiermann W, Rezai M, Kummel S, Kuhn T, Warm M, Friedrichs K, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013;24:618-624 https://doi.org/10.1093/annonc/mds512
  37. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015;373:2005-2014 https://doi.org/10.1056/NEJMoa1510764
  38. Stemmer S, Steiner M, Rizel S, Ben-Baruch N, Soussan-Gutman L, Rosengarten O, et al. 1963 first prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-gene recurrence score. European Journal of Cancer 2015;51:S321
  39. Stemmer S, Steiner M, Rizel S, Soussan-Gutman L, Geffen DB, Nisenbaum B, et al. Abstract P5-08-02: real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%. Cancer Research 2016;76(4 Suppl):Abstract nr P5-08-02
  40. Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. West German Study Group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016;34:2341-2349 https://doi.org/10.1200/JCO.2015.63.5383
  41. Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer 2016;2:16017
  42. Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013;133:929-936 https://doi.org/10.1002/ijc.28082
  43. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al.; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011;17:6012-6020 https://doi.org/10.1158/1078-0432.CCR-11-0926
  44. Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, et al.; Austrian Breast and Colorectal Cancer Study Group (ABCSG). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013;24:640-647 https://doi.org/10.1093/annonc/mds334
  45. Filipits M, Nielsen TO, Rudas M, Greil R, Stoger H, Jakesz R, et al.; Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014;20:1298-1305 https://doi.org/10.1158/1078-0432.CCR-13-1845
  46. Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 2015;33:916-922 https://doi.org/10.1200/JCO.2014.55.6894
  47. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067-1076 https://doi.org/10.1016/S1470-2045(13)70387-5
  48. Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013;19:4196-4205 https://doi.org/10.1158/1078-0432.CCR-13-0804
  49. Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, et al. Bioscore: a staging system for breast cancer patients that reflects the prognostic significance of underlying tumor biology. Ann Surg Oncol 2017;24:3502-3509 https://doi.org/10.1245/s10434-017-6009-x